Your session is about to expire
← Back to Search
Chemokine Receptor Antagonist
Reparixin for Myelofibrosis
Phase 2
Recruiting
Research Sponsored by Icahn School of Medicine at Mount Sinai
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up end of study (24 weeks) plus 3 months
Awards & highlights
Study Summary
This trial will assess the safety and effectiveness of Reparixin in treating patients with intermediate-2 or high-risk primary myelofibrosis, post ET/PV myelofibrosis, or who are ineligible/refuse treatment with JAKi. 26 patients will be enrolled and receive Reparixin 3x/day for 6 cycles (24 wks). Continued treatment if SD is met.
Who is the study for?
This trial is for adults with intermediate-2 or high-risk primary myelofibrosis, post-ET/PV MF who have not responded well to JAK inhibitor treatment or can't take it. Participants should be in good enough health to perform daily activities with minimal assistance (ECOG ≤ 2), have proper organ function, and a life expectancy of at least six months. Pregnant women and those with recent severe heart issues, active serious infections, or other unstable conditions are excluded.Check my eligibility
What is being tested?
The study tests the efficacy and safety of Reparixin taken orally three times daily over a 24-week period in patients with certain types of myelofibrosis after previous treatments have failed. The trial aims to enroll 26 patients who may continue treatment if they show no disease progression after the initial cycles.See study design
What are the potential side effects?
While specific side effects for Reparixin are not listed here, common side effects from drugs treating similar conditions include digestive issues like nausea and diarrhea, potential liver enzyme changes, fatigue, risk of infection due to weakened immune systems, bleeding complications such as hematoma or hemorrhage.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ end of study (24 weeks) plus 3 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~end of study (24 weeks) plus 3 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Efficacy of reparixin treatment per IWG/ELN criteria
Secondary outcome measures
Bone marrow fibrosis grade
Change in Spleen Volume
Number of Adverse Events
+1 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: ReparixinExperimental Treatment1 Intervention
Eligible patients will receive oral reparixin three times daily on a 4-week cycle for a core study period of 6 cycles (24 weeks). After cycle 6, patients may continue receiving reparixin once daily on a 4-week cycle if at least stable disease (SD) is met by IWG-MRT criteria until loss of response, disease progression, unacceptable toxicity, patient/physician withdrawal, or termination of study by sponsor.
Find a Location
Who is running the clinical trial?
Dompé Farmaceutici S.p.AIndustry Sponsor
49 Previous Clinical Trials
4,508 Total Patients Enrolled
Icahn School of Medicine at Mount SinaiLead Sponsor
862 Previous Clinical Trials
525,600 Total Patients Enrolled
3 Trials studying Primary Myelofibrosis
1,572 Patients Enrolled for Primary Myelofibrosis
NovartisIndustry Sponsor
1,611 Previous Clinical Trials
2,721,009 Total Patients Enrolled
9 Trials studying Primary Myelofibrosis
1,278 Patients Enrolled for Primary Myelofibrosis
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I had a stem cell transplant less than 100 days ago.It has been over two weeks since my last myelofibrosis treatment.I haven't used any experimental drugs or devices in the last 4 weeks.I have moderate or severe heart disease.I am currently dealing with a serious infection.My stomach or intestines have issues that could affect how a medicine is absorbed.I am not pregnant or breastfeeding.I am able to get out of my bed or chair and move around.I have recovered from previous cancer treatment side effects, except for hair loss.My condition is a type of advanced myelofibrosis diagnosed by specific criteria.My organs are functioning well.I am 18 years old or older.I have not had a heart attack or stroke in the last 6 months.I do not have any serious health or mental conditions that would stop me from joining the study.I have a history of HIV or active hepatitis A, B, or C.I am willing to have a bone marrow biopsy or had one in the last 90 days without any treatments in between.My condition did not improve with JAK inhibitor therapy.I haven't had any cancer except for skin, prostate, or cervical cancer in the last 3 years.
Research Study Groups:
This trial has the following groups:- Group 1: Reparixin
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What potential risks are associated with Reparixin usage?
"Our team at Power assigned Reparixin a safety rating of 2, as there is evidence to back up its safety but none that supports efficacy given it is only in Phase 2."
Answered by AI
Are there any available openings for this experiment currently?
"Unfortunately, the clinicaltrials.gov website affirms that this medical trial is no longer recruiting candidates; however, there are a plethora of other studies with open enrollment at present - totalling 2669 different trials. The initial posting date for this study was on May 1st 2023 and it received its most recent update on April 18th 2023."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger